AyuVis Research
View On Demand

AyuVis is developing a new class of drugs

About the Event


AyuVis is developing a new class of drugs with broad-based applications that include the treatment of some of today’s most common and debilitating diseases. The initial list includes Sepsis, Renal Disease, Acute Respiratory Distress Syndrome (ARDS), as well as other respiratory, ocular, and dermatology applications. All together, the global market opportunity for these indications exceeds $100B annually.

AyuVis compounds are unique thanks to their triple action immunomodulation, anti-inflammatory, and anti-microbial activities. The flexibility of this platform creates the potential to treat many more indications than a single-target compound. 

Please join our webinar with AyuVis founder and CEO, Dr. Suchi Acharya and her team, who will talk about the expedited approval process for AVR-48 which has received an Orphan Drug Designation from the FDA and the other opportunities for the compound which have the potential to exceed $100B annually.

View On-Demand


SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.